Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

Pharma Industry Outlook: What Lies Ahead?

With 2023 well underway, the crucial question is: how will the bio/pharmaceutical industry perform in 2023 and the near term? The DCAT Week program, Pharma Industry Outlook, will provide key market data and trends. Plus, a pharma financial outlook and analysis of M&A, partnering deals, and private and public financing into Emerging Pharma. 

With 2023 well underway, the crucial question is: how will the bio/pharmaceutical industry perform in 2023 and the near term? The DCAT Week program, Pharma Industry Outlook, will provide key market data and trends. Plus, a pharma financial outlook and analysis of M&A, partnering deals, and private and public financing into Emerging Pharma. 

What are the key growth indicators for the global bio/pharmaceutical market in 2023 and over the next five years, and how will the industry perform over this time. That is the operative question for bio/pharma companies and their suppliers, 

Graham Lewis
Vice President,
Global Pharma Strategy
IQVIA

DCAT Week’s flagship program, Pharma Industry Outlook, will answer that question by providing need-to-know market intelligence on the current and projected performance of the bio/pharma industry. Graham Lewis, Vice President of Global Pharma Strategy, IQVIA, a business intelligence firm regarded as the gold standard for bio/pharmaceutical market analysis, will provide the latest market data and trends. 

A key issue is how the industry will perform in the post-pandemic environment with the transition of the global COVID-19 pandemic to a new phase where vaccines and therapeutics are available but are used at different levels and if growth will return to pre-pandemic levels. The program will address these all-important questions:

  • What are the growth prospects globally and in key geographic markets?
  • How is the industry faring in new drug development and what can be expected near term? 
  • Where is the growth in small molecules, biologics, and new modalities such as cell and gene therapies?

Financial outlook for Emerging Pharma
Small bio/pharmaceutical companies play an increasingly important role in product innovation for the industry, but what is the financial outlook for this sector?

Arda Ural,
EY Americas Health Sciences and Wellness Industry Markets Leader, Ernst & Young (EY)

Arda Ural, PhD, EY Americas Health Sciences and Wellness Industry Markets Leader, Ernst & Young (EY), will examine the key trends in industry deal-making and capital flow into Emerging Pharma, a vital customer base for CDMOs/CMOs and partner for bio/pharma companies.  

Pharma Industry Outlook will be held at the InterContinental Barclay Hotel, Grand Ballroom on Monday, March 20, 2023: 2:30 – 4:30 PM; Doors open at 2:00 PM for networking. Plus, Post-Program Attendee Networking Reception: 4:30 to 6:00 PM.  

Register or learn more about this program here. 

Recent Feature Articles

The Battle of the Blockbusters: GLP-1 Agonists

By
GLP-1 agonist drugs, in the form of Novo Nordisk’s Wegvoy/Ozempic, and Lilly’s Mounjaro for weight management and treating Type II diabetes, were blockbuster winners in 2023, putting this therapeutic sector into high focus. What has been the impact on manufacturing and what are other contenders in this high-growth sector?

Manufacturing & Supply Lines: Small-Molecule APIs

By
Small-molecule drugs still dominate new drug approvals, as measured by the number of new molecular entities approved by the FDA’s Center for Drug Evaluation and Research, but are they translating into market success? DCAT Value Chain Insights takes a look on the market for drugs with small-molecule active pharmaceutical ingredients and related supply–demand fundamentals.

European Parliament Takes Next Step in Reforming EU Pharma Legislation

By
The European Parliament adopted its positions on proposals to revamp the EU‘s pharmaceutical legislation, which includes measures impacting drug development, commercialization, manufacturing & the supply chain. European innovator & generic-drug companies weigh in.

What’s Trending: Generic Drugs by the Numbers & Key Market Developments

By
Generic-drug approvals in the US reached a recent high in 2023 although the number of first-generic approvals were down comparative to recent years. DCAT Value Chain Insights takes a look inside the numbers and the key market moves from the leading generic-drug companies.